ꯕ꯭ꯂꯣꯒꯁꯤꯡꯒꯤ ꯑꯀꯨꯞꯄꯥ ꯃꯔꯣꯜ꯫
ꯌꯦꯡꯈꯤꯕꯥ: 5214 ꯂꯤꯈꯨꯟ: yourxc ꯐꯣꯉꯕꯥ ꯃꯇꯝ: ꯲꯰꯲꯶-꯱꯰-꯳꯱ ꯍꯧꯔꯀꯐꯝ: ꯃꯐꯝ
ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯁꯦꯛꯁꯟꯗꯥ ꯁꯤꯖꯤꯟꯅꯕꯥ ꯍꯧꯔꯀꯄꯥ ꯑꯅꯥꯕꯥ ꯂꯤꯁꯤꯡ ꯀꯌꯥꯅꯥ ꯍꯧꯖꯤꯛ ꯆꯞ ꯃꯥꯟꯅꯕꯥ ꯋꯥꯍꯪ ꯍꯪꯂꯤ: ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯑꯃꯨꯛ ꯍꯟꯅꯥ ꯋꯦꯒꯣꯚꯤꯗꯥ ꯆꯪꯁꯤꯅꯕꯒꯤ ꯃꯇꯝ ꯑꯣꯏꯕꯔꯥ, ꯑꯃꯁꯨꯡ ꯁꯣꯏꯆ ꯑꯁꯤ ꯀꯔꯝꯅꯥ ꯁꯥꯐꯅꯥ ꯇꯧꯒꯗꯒꯦ? ꯍꯤꯗꯥꯛ ꯑꯅꯤꯃꯛ ꯑꯁꯤ ꯅꯣꯚꯣ ꯅꯣꯔꯗꯤꯁ꯭ꯀꯅꯥ ꯁꯦꯝꯕꯥ ꯖꯤ.ꯑꯦꯜ.ꯄꯤ.-꯱ ꯔꯤꯁꯦꯄꯇꯔ ꯑꯦꯒꯣꯅꯤꯁ꯭ꯇꯁꯤꯡꯅꯤ, ꯑꯗꯨꯕꯨ ꯃꯈꯣꯌꯅꯥ ꯇꯣꯉꯥꯟ ꯇꯣꯉꯥꯅꯕꯥ ꯃꯣꯂꯤꯛꯌꯨꯂꯁꯤꯡ (ꯂꯤꯔꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ ꯕꯅꯥꯝ ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ), ꯇꯣꯉꯥꯟ ꯇꯣꯉꯥꯅꯕꯥ ꯗꯣꯖꯒꯤ ꯔꯤꯗꯃꯁꯤꯡ ꯑꯃꯁꯨꯡ ꯇꯣꯉꯥꯟ ꯇꯣꯉꯥꯅꯕꯥ ꯇꯤꯇꯥꯔꯦꯁꯟ ꯁꯦꯗ꯭ꯌꯨꯂꯁꯤꯡ ꯁꯤꯖꯤꯟꯅꯩ꯫ ꯇ꯭ꯔꯥꯟꯁꯤꯁꯟ ꯔꯥꯏꯠ ꯐꯪꯕꯅꯥ ꯇꯣꯂꯦꯔꯦꯕꯤꯂꯤꯇꯤ ꯉꯥꯀꯊꯣꯀꯏ, ꯑꯔꯨꯝꯕꯥ ꯍꯟꯊꯍꯅꯕꯒꯤ ꯃꯣꯃꯦꯟꯇꯝ ꯊꯝꯃꯤ ꯑꯃꯁꯨꯡ ꯗ꯭ꯔꯒ ꯑꯅꯤ ꯑꯁꯤ ꯑꯣꯚꯔꯂꯦꯞ ꯇꯧꯕꯒꯨꯝꯕꯥ ꯀꯃꯟ ꯑꯣꯏꯕꯥ ꯑꯁꯣꯏꯕꯁꯤꯡꯗꯒꯤ ꯉꯥꯀꯊꯣꯀꯏ꯫
ꯀꯔꯤꯒꯨꯝꯕꯥ ꯅꯍꯥꯛꯅꯥ ꯀꯔꯝꯕꯥ ꯗ꯭ꯔꯒꯅꯥ ꯑꯅꯥꯕꯥ ꯑꯃꯗꯥ ꯆꯨꯝꯃꯤ ꯍꯥꯌꯕꯗꯨ ꯍꯦꯗ-ꯇꯨ-ꯍꯦꯗ ꯂꯨꯛ ꯑꯃꯥ ꯄꯥꯝꯂꯕꯗꯤ, ꯑꯩꯈꯣꯌꯒꯤ ꯍꯥꯟꯅꯒꯤ ꯒꯥꯏꯗꯂꯥꯏꯟ, ꯋꯦꯒꯣꯚꯤ ꯑꯃꯁꯨꯡ ꯁꯦꯛꯁꯟꯗꯥ ꯆꯥꯡꯗꯝꯅꯕꯥ: ꯑꯔꯨꯝꯕꯥ ꯍꯟꯊꯍꯅꯕꯒꯤ ꯍꯤꯗꯥꯛ ꯑꯁꯤ ꯅꯍꯥꯛꯀꯤꯗꯃꯛꯇꯥ ꯆꯨꯝꯃꯤ . ꯑꯥꯔꯇꯤꯀꯜ ꯑꯁꯤꯅꯥ ꯇꯣꯉꯥꯅꯕꯥ ꯋꯥꯐꯝ ꯑꯃꯗꯥ ꯃꯤꯠꯌꯦꯡ ꯊꯝꯂꯤ: ꯁꯦꯛꯁꯟꯗꯥꯗꯒꯤ ꯋꯦꯒꯣꯚꯤꯗꯥ ꯍꯣꯡꯗꯣꯀꯄꯒꯤ ꯊꯧꯑꯣꯡ, ꯃꯇꯝ, ꯍꯧꯗꯣꯀꯄꯒꯤ ꯗꯣꯖ, ꯇꯤꯇꯔꯦꯁꯟ ꯑꯃꯁꯨꯡ ꯑꯍꯥꯅꯕꯥ ꯊꯥꯁꯤꯡꯗꯥ ꯑꯅꯥꯕꯁꯤꯡ ꯑꯃꯁꯨꯡ ꯀ꯭ꯂꯤꯅꯤꯀꯁꯤꯡꯅꯥ ꯀꯔꯤ ꯉꯥꯏꯒꯗꯒꯦ ꯍꯥꯌꯕꯗꯨ ꯀꯣꯅꯁꯤꯜꯂꯤ꯫
ꯀ꯭ꯂꯤꯅꯤꯁꯤꯌꯅꯁꯤꯡꯅꯥ ꯁꯦꯛꯁꯟꯗꯥ ꯋꯦꯒꯣꯚꯤ ꯇ꯭ꯔꯥꯟꯁꯤꯁꯟ ꯑꯃꯥ ꯑꯣꯏꯅꯥ ꯂꯧꯅꯕꯒꯤ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯀꯃꯟ ꯑꯣꯏꯕꯥ ꯃꯔꯃꯁꯤꯡꯗꯤ:
ꯆꯥꯡꯆꯠꯇꯥ ꯑꯔꯨꯝꯕꯥ ꯍꯦꯅꯒꯠꯂꯀꯄꯥ꯫ STEP 8 ꯔꯦꯟꯗꯝ ꯑꯣꯏꯕꯥ ꯇ꯭ꯔꯥꯏꯑꯦꯂꯗꯥ, ꯗꯥꯏꯑꯦꯕꯦꯇꯤꯖ ꯂꯩꯇꯕꯥ ꯑꯍꯂꯁꯤꯡꯅꯥ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 2.4 ꯄꯤꯕꯅꯥ ꯍꯀꯆꯥꯡꯒꯤ ꯑꯔꯨꯝꯕꯥ 15.8% ꯍꯟꯊꯈꯤ, ꯃꯁꯤ ꯅꯨꯃꯤꯠ 68ꯅꯤꯒꯤ ꯃꯅꯨꯡꯗꯥ ꯅꯣꯡꯃꯗꯥ ꯂꯤꯔꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 3.0 ꯄꯤꯕꯗꯥ 6.4% ꯍꯟꯊꯈꯤ (ꯔꯨꯕꯤꯅꯣ ꯑꯃꯁꯨꯡ ꯑꯦꯜ., ꯖꯥꯃꯥ 2022)꯫
ꯏꯅꯖꯦꯀꯁꯟ ꯍꯟꯊꯕꯥ꯫ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯏꯅꯖꯦꯀꯁꯟ ꯑꯃꯥ ꯷ ꯄꯤꯕꯒꯤ ꯃꯍꯨꯠꯇꯥ ꯏꯅꯖꯦꯀꯁꯟ ꯑꯃꯥ ꯄꯤꯕꯅꯥ ꯃꯤꯑꯣꯏ ꯀꯌꯥꯗꯥ ꯑꯦꯗꯍꯦꯟꯁ ꯇꯧꯕꯗꯥ ꯂꯥꯌꯍꯜꯂꯤ꯫
ꯁꯛꯁꯦꯟꯗꯥ ꯂꯩꯕꯥ ꯄ꯭ꯂꯦꯠꯐꯣꯔꯝ ꯑꯃꯥ꯫ ꯁꯦꯛꯁꯟꯗꯥ ꯂꯦꯕꯦꯂꯅꯥ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯑꯍꯜ ꯑꯃꯅꯥ ꯅꯨꯃꯤꯠ 16ꯅꯤꯒꯤ ꯃꯇꯨꯡꯗꯥ ꯌꯥꯃꯗ꯭ꯔꯕꯗꯥ ꯕꯦꯖ ꯂꯥꯏꯅꯒꯤ ꯑꯔꯨꯝꯕꯥ 4% ꯍꯟꯊꯔꯛꯠꯔꯕꯗꯤ ꯂꯥꯏꯌꯦꯡ ꯊꯤꯡꯅꯕꯥ ꯄꯥꯎꯇꯥꯛ ꯄꯤꯔꯤ, ꯃꯁꯤꯅꯥ ꯄ꯭ꯔꯦꯁ꯭ꯛꯔꯥꯏꯕꯔ ꯀꯌꯥꯅꯥ ꯑꯂꯇꯔꯅꯦꯇꯤꯚꯁꯤꯡ ꯔꯤꯚꯤꯌꯨ ꯇꯧꯅꯕꯥ ꯄꯨꯛꯅꯤꯡ ꯊꯧꯒꯠꯂꯤ꯫
ꯁꯞꯂꯥꯏ, ꯃꯃꯜ ꯅꯠꯠꯔꯒꯥ ꯏꯟꯁꯨꯔꯦꯟꯁꯇꯥ ꯑꯍꯣꯡꯕꯥ ꯂꯥꯀꯄꯥ , ꯃꯗꯨ ꯂꯩꯕꯥꯛ ꯑꯃꯒꯤ ꯃꯇꯨꯡ ꯏꯟꯅꯥ ꯈꯦꯠꯅꯩ ꯑꯃꯁꯨꯡ ꯆꯥꯡ ꯅꯥꯏꯅꯥ ꯍꯣꯡꯏ꯫
ꯁꯣꯏꯆ ꯇꯧꯕꯥ ꯍꯥꯌꯕꯁꯤ ꯇꯉꯥꯏꯐꯗꯕꯥ ꯅꯠꯇꯦ꯫ ꯌꯨ.ꯑꯦꯁ.ꯀꯤ ꯚꯦꯇꯔꯥꯟ ꯑꯦꯐꯦꯌꯔꯁꯀꯤ ꯀꯟꯕꯔꯁꯟ ꯒꯥꯏꯗꯂꯥꯏꯅꯁꯤꯡꯅꯥ ꯅꯣꯠ ꯇꯧꯔꯤ ꯃꯗꯨꯗꯤ ꯂꯤꯔꯥꯒ꯭ꯂꯨꯇꯥꯏꯗꯇꯥ ꯐꯖꯅꯥ ꯊꯕꯛ ꯇꯧꯔꯤꯕꯥ ꯑꯃꯁꯨꯡ ꯑꯔꯨꯝꯕꯥ ꯍꯟꯊꯔꯀꯄꯥ ꯑꯅꯥꯕꯥ ꯑꯃꯕꯨ ꯀꯟꯕꯔꯁꯟ ꯇꯧꯕꯒꯤ ꯃꯊꯧ ꯇꯥꯗꯦ꯫ ꯋꯥꯔꯦꯞ ꯑꯁꯤ ꯃꯇꯝ ꯄꯨꯝꯅꯃꯛꯇꯥ ꯃꯤꯑꯣꯏ ꯑꯃꯃꯃꯒꯤ ꯑꯣꯏꯒꯗꯕꯅꯤ꯫
ꯑꯣꯐꯤꯁꯤꯑꯦꯜ ꯌꯨ.ꯑꯦꯁ.ꯀꯤ ꯄ꯭ꯔꯦꯁꯛꯔꯤꯄꯁꯟ ꯏꯅꯐꯣꯔꯃꯦꯁꯅꯒꯤ ꯃꯇꯨꯡ ꯏꯟꯅꯥ:
ꯁꯦꯛꯁꯟꯗꯥ (ꯂꯤꯔꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ) ꯑꯁꯤ ꯁꯕꯛꯌꯨꯇꯦꯅꯤꯌꯝ ꯑꯣꯏꯅꯥ ꯏꯅꯖꯦꯀꯁꯟ ꯇꯧꯏ ꯅꯣꯡꯃꯗꯥ ꯑꯃꯨꯛ ꯍꯟꯅꯥ . ꯃꯁꯤ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 0.6ꯗꯒꯤ ꯍꯧꯏ ꯑꯃꯁꯨꯡ ꯅꯨꯃꯤꯠ 5ꯅꯤꯒꯤ ꯑꯣꯏꯅꯥ ꯅꯣꯡꯃꯗꯥ ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 3ꯒꯤ ꯃꯦꯟꯇꯤꯅꯦꯟꯁ ꯗꯣꯖ ꯑꯗꯨ ꯌꯧꯗ꯭ꯔꯤꯉꯩꯗꯥ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 0.6 (ꯃꯤꯒ꯭ꯔꯦꯗ 1.2, ꯃꯤꯒ꯭ꯔꯦꯗ 1.8, ꯃꯤꯒ꯭ꯔꯦꯗ 2.4) ꯍꯦꯅꯒꯠꯂꯀꯏ, ꯍꯦꯟꯅꯥ ꯅꯦꯝꯕꯥ ꯗꯣꯖꯁꯤꯡ ꯑꯁꯤ ꯇꯤꯇꯥꯔꯦꯁꯟ ꯈꯛꯇꯒꯤꯅꯤ꯫
ꯋꯦꯒꯣꯚꯤ (semaglutide) ꯏꯅꯖꯦꯀꯁꯟ ꯑꯁꯤ ꯁꯕꯛꯌꯨꯇꯦꯅꯤꯌꯝ ꯑꯣꯏꯅꯥ ꯄꯤꯖꯩ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯑꯃꯨꯛ ꯍꯟꯅꯥ , ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯅꯨꯃꯤꯠ ꯑꯃꯗꯥ ꯄꯤ꯫ ꯑꯦꯁ꯭ꯀꯦꯂꯦꯁꯅꯒꯤ ꯃꯇꯝ ꯑꯁꯤ:
ꯅꯨꯃꯤꯠ 1–4ꯅꯤꯒꯤ ꯃꯅꯨꯡꯗꯥ: 0.25 mg
ꯅꯨꯃꯤꯠ 5–8ꯅꯤꯒꯤ ꯃꯅꯨꯡꯗꯥ: 0.5 mg
ꯅꯨꯃꯤꯠ 9–12ꯅꯤꯒꯤ ꯃꯅꯨꯡꯗꯥ: 1 mg
ꯅꯨꯃꯤꯠ 13–16ꯅꯤꯒꯤ ꯃꯅꯨꯡꯗꯥ: 1.7 mg
ꯅꯨꯃꯤꯠ 17ꯅꯤꯒꯤ ꯃꯇꯨꯡꯗꯥ: ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 2.4 (ꯔꯦꯀꯃꯦꯟꯗ ꯇꯧꯔꯕꯥ) ꯅꯠꯠꯔꯒꯥ ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 1.7ꯒꯤ ꯃꯦꯟꯇꯤꯅꯦꯟꯁ꯫
ꯍꯧꯖꯤꯛ ꯂꯩꯔꯤꯕꯥ ꯌꯨ.ꯑꯦꯁ.ꯀꯤ ꯂꯦꯕꯦꯜ ꯑꯁꯤꯅꯥ ꯌꯥꯃꯗ꯭ꯔꯕꯗꯥ ꯅꯨꯃꯤꯠ ꯴ꯅꯤꯒꯤ ꯑꯣꯏꯅꯥ ꯃꯤꯒ꯭ꯔꯦꯗ ꯲.꯴ ꯇꯦꯂꯦꯔꯦꯠ ꯇꯧꯔꯕꯥ ꯑꯍꯂꯁꯤꯡꯗꯁꯨ ꯃꯈꯥ ꯇꯥꯅꯥ ꯑꯔꯨꯝꯕꯥ ꯍꯟꯊꯍꯅꯕꯥ ꯍꯥꯌꯕꯁꯤ ꯀ꯭ꯂꯤꯅꯤꯀꯦꯜ ꯑꯣꯏꯅꯥ ꯇꯥꯀꯄꯥ ꯃꯇꯃꯗꯥ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯌꯥꯝꯅꯥ ꯃꯤꯒ꯭ꯔꯦꯗ ꯷.꯲ ꯐꯥꯑꯣꯕꯥ ꯍꯦꯅꯒꯠꯍꯅꯕꯥ ꯌꯥꯍꯜꯂꯤ꯫ ꯗꯣꯖ ꯑꯃꯁꯨꯡ ꯐꯪꯂꯤꯕꯥ ꯄꯥꯉ꯭ꯒꯜ ꯑꯁꯤ ꯂꯩꯕꯥꯛ ꯑꯃꯒꯤ ꯃꯇꯨꯡꯏꯟꯅꯥ ꯈꯦꯠꯅꯩ, ꯃꯔꯝ ꯑꯗꯨꯅꯥ ꯃꯇꯝ ꯄꯨꯝꯅꯃꯛꯇꯥ ꯃꯐꯃꯗꯨꯒꯤ ꯂꯦꯕꯦꯜ ꯑꯗꯨ ꯏꯅꯒꯗꯕꯅꯤ꯫ ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗꯅꯥ ꯀꯔꯝꯅꯥ ꯊꯕꯛ ꯇꯧꯕꯒꯦ ꯍꯥꯌꯕꯒꯤ ꯕꯦꯀꯒ꯭ꯔꯥꯎꯟꯗꯒꯤꯗꯃꯛ, ꯄꯥꯕꯤꯌꯨ꯫ ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ ꯏꯅꯖꯦꯀꯁꯟ ꯑꯃꯁꯨꯡ ꯃꯁꯤꯒꯤ ꯁꯤꯖꯤꯟꯅꯐꯃꯁꯤꯡ ꯈꯪꯖꯤꯅꯕꯥ꯫.
ꯂꯦꯕꯦꯜ ꯑꯅꯤꯃꯛꯇꯥ ꯗ꯭ꯔꯒ ꯑꯁꯤ ꯑꯇꯣꯞꯄꯥ ꯖꯤ.ꯑꯦꯜ.ꯄꯤ.-꯱ ꯔꯤꯁꯦꯄꯇꯔ ꯑꯦꯒꯣꯅꯤꯁ꯭ꯠ ꯑꯃꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯁꯤꯖꯤꯟꯅꯔꯣꯏꯗꯕꯅꯤ ꯍꯥꯌꯅꯥ ꯐꯣꯉꯗꯣꯛꯂꯤ꯫ ꯑꯗꯨꯒꯨꯝꯕꯥ ꯅꯤꯌꯝ ꯑꯃꯈꯛꯇꯅꯥ ꯁꯣꯏꯆ ꯇꯧꯕꯒꯤ ꯊꯧꯑꯣꯡ ꯄꯨꯝꯅꯃꯛ ꯃꯑꯣꯡ ꯁꯦꯝꯃꯤ꯫
ꯋꯦꯒꯣꯚꯤ ꯅꯠꯔꯒꯥ ꯁꯦꯛꯁꯟꯗꯥ ꯂꯦꯕꯦꯜ ꯑꯃꯠꯇꯥꯗꯥ ꯑꯣꯐꯤꯁꯤꯑꯦꯜ ꯑꯣꯏꯕꯥ ꯁꯦꯛꯁꯟꯗꯥ-ꯇꯨ-ꯋꯦꯒꯣꯚꯤ ꯁꯣꯏꯆꯤꯡ ꯄ꯭ꯔꯣꯇꯣꯀꯣꯜ ꯑꯃꯠꯇꯥ ꯌꯥꯑꯣꯗꯦ꯫ ꯃꯈꯥꯗꯥ ꯄꯤꯔꯤꯕꯥ ꯑꯁꯤꯅꯥ ꯐꯣꯉꯗꯣꯛꯂꯕꯥ ꯀ꯭ꯂꯤꯅꯤꯀꯦꯜ ꯒꯥꯏꯗꯂꯥꯏꯅꯁꯤꯡ ꯑꯃꯁꯨꯡ ꯀꯃꯟ ꯄ꯭ꯔꯦꯛꯇꯤꯁꯀꯤ ꯃꯃꯤ ꯇꯥꯔꯤ꯫ ꯄ꯭ꯔꯦꯁ꯭ꯛꯔꯥꯏꯕꯔ ꯑꯗꯨꯅꯥ ꯃꯇꯝ ꯄꯨꯝꯅꯃꯛꯇꯥ ꯑꯔꯣꯏꯕꯥ ꯀꯣꯜ ꯑꯗꯨ ꯇꯧꯏ꯫
ꯀ꯭ꯂꯤꯅꯤꯁꯤꯌꯅꯁꯤꯡꯅꯥ ꯑꯍꯥꯅꯕꯗꯥ ꯀꯔꯤꯒꯤꯗꯃꯛꯇꯥ ꯄꯦꯁꯦꯟꯇ ꯑꯗꯨꯅꯥ ꯍꯣꯡꯗꯣꯀꯄꯥ ꯄꯥꯝꯂꯤꯕꯅꯣ ꯍꯥꯌꯕꯗꯨ ꯀꯅꯐꯥꯔꯝ ꯇꯧꯏ, ꯃꯗꯨ ꯏꯐꯤꯁꯤꯑꯦꯟꯁꯤ, ꯈꯨꯗꯣꯡꯆꯥꯕꯥ, ꯃꯃꯜ ꯅꯠꯠꯔꯒꯥ ꯁꯥꯏꯗ ꯏꯐꯦꯛꯇ ꯑꯣꯏꯔꯕꯁꯨ꯫ ꯃꯗꯨꯒꯤ ꯃꯇꯨꯡꯗꯥ ꯃꯈꯣꯌꯅꯥ ꯀꯟꯠꯔꯣꯂꯁꯤꯡ ꯑꯗꯨ ꯑꯃꯨꯛ ꯍꯟꯅꯥ ꯌꯦꯡꯁꯤꯜꯂꯤ꯫ ꯋꯦꯒꯣꯚꯤ ꯑꯁꯤ ꯃꯦꯗꯨꯂꯦꯔꯤ ꯊꯥꯏꯔꯣꯏꯗ ꯀꯥꯔꯁꯤꯅꯣꯃꯥ ꯅꯠꯠꯔꯒꯥ MEN 2ꯒꯤ ꯄꯔꯁꯣꯅꯦꯜ ꯅꯠꯠꯔꯒꯥ ꯐꯦꯃꯤꯂꯤ ꯍꯤꯁ꯭ꯇꯔꯤ ꯂꯩꯕꯥ ꯄꯦꯁꯦꯟꯇꯁꯤꯡꯗꯥ ꯁꯤꯖꯤꯟꯅꯔꯣꯏꯗꯕꯅꯤ, ꯑꯃꯁꯨꯡ ꯇꯥꯏꯞ 2 ꯗꯥꯏꯑꯦꯕꯦꯇꯤꯖ ꯂꯩꯕꯥ ꯃꯤꯑꯣꯏꯁꯤꯡꯅꯥ ꯑꯍꯣꯡꯕꯥ ꯑꯁꯤꯒꯤ ꯃꯅꯨꯡꯗꯥ ꯒ꯭ꯂꯨꯀꯣꯖ ꯃꯣꯅꯤꯇꯔ ꯇꯧꯕꯥ ꯃꯊꯧ ꯇꯥꯏ꯫
ꯐꯣꯉꯕꯥ ꯄ꯭ꯔꯦꯛꯇꯤꯀꯦꯜ ꯒꯥꯏꯗꯂꯥꯏꯅꯁꯤꯡ ꯀ꯭ꯂꯤꯅꯤꯀꯦꯜ ꯗꯥꯏꯕꯦꯇꯤꯁꯇꯥ (ꯑꯂꯃꯥꯟꯗꯣꯖ, ꯂꯤꯡꯚꯥꯏ ꯑꯃꯁꯨꯡ ꯃꯣꯔꯥꯂꯦꯁ, ꯲꯰꯲꯰)ꯅꯥ ꯇꯥꯛꯂꯤ ꯃꯗꯨꯗꯤ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯖꯤ.ꯑꯦꯜ.ꯄꯤ.-꯱ ꯑꯦꯒꯣꯅꯤꯁ꯭ꯠ ꯑꯃꯥ ꯃꯄꯨꯡ ꯐꯥꯕꯥ ꯗꯣꯖꯗꯥ ꯇꯦꯂꯦꯔꯦꯠ ꯇꯧꯕꯥ ꯄꯦꯁꯦꯟꯇ ꯑꯃꯅꯥ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯑꯦꯖꯦꯟꯇ ꯑꯁꯤ ꯑꯔꯣꯏꯕꯥ ꯅꯣꯡꯃꯒꯤ ꯗꯣꯖꯒꯤ ꯃꯇꯨꯡ ꯅꯨꯃꯤꯠꯇꯥ ꯍꯧꯕꯥ ꯌꯥꯏ . ꯅ꯭ꯌꯨ ꯖꯤꯂꯦꯟꯗꯒꯤ ꯀ꯭ꯔꯤꯁꯆꯔ ꯃꯦꯗꯤꯁꯤꯅꯁ ꯏꯅꯐꯣꯔꯃꯦꯁꯟ ꯁꯔꯚꯤꯁ (2025)ꯅꯥ ꯃꯇꯧ ꯑꯁꯨꯝꯅꯥ ꯋꯥꯁꯛ ꯂꯧꯕꯒꯤ ꯃꯇꯝ ꯑꯃꯠꯇꯥ ꯃꯊꯧ ꯇꯥꯗꯦ ꯍꯥꯌꯅꯥ ꯐꯣꯡꯗꯣꯛꯂꯤ꯫ ꯗ꯭ꯔꯒ ꯑꯅꯤꯃꯛ ꯄꯨꯟꯅꯥ ꯂꯧꯕꯥ ꯍꯥꯌꯕꯁꯤ ꯂꯦꯕꯦꯜ ꯑꯃꯠꯇꯒꯤ ꯃꯈꯥꯗꯥ ꯔꯦꯀꯃꯦꯟꯗ ꯇꯧꯗꯦ꯫
ꯃꯁꯤꯒꯤ ꯑꯦꯛꯁꯦꯞꯁꯟ ꯑꯃꯗꯤ ꯂꯩ꯫ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯁꯣꯏꯆ ꯑꯁꯤ ꯒꯦꯁ꯭ꯠꯔꯣꯏꯟꯇꯦꯁ꯭ꯇꯦꯅꯤꯑꯦꯜ ꯁꯥꯏꯗ ꯏꯐꯦꯛꯇꯅꯥ ꯃꯔꯝ ꯑꯣꯏꯗꯨꯅꯥ ꯊꯣꯛꯂꯕꯗꯤ , ꯆꯞ ꯃꯥꯟꯅꯕꯥ ꯒꯥꯏꯗꯂꯥꯏꯅꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯁꯦꯛꯁꯟꯗꯥ ꯊꯤꯡꯅꯕꯥ ꯑꯃꯁꯨꯡ ꯋꯦꯒꯣꯚꯤ ꯑꯁꯤ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯅꯦꯝꯕꯥ ꯗꯣꯖꯗꯥ ꯍꯧꯗ꯭ꯔꯤꯉꯩꯗꯥ ꯂꯥꯏꯑꯣꯡꯁꯤꯡ ꯑꯗꯨ ꯂꯥꯀꯁꯤꯜꯂꯛꯠꯔꯤꯕꯐꯥꯎꯕꯥ ꯉꯥꯏꯅꯕꯥ ꯄꯥꯎꯇꯥꯛ ꯄꯤꯔꯤ꯫
ꯅꯣꯡꯃꯗꯥ ꯂꯤꯔꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ ꯳ ꯃꯤꯒ꯭ꯔꯥ ꯑꯃꯁꯨꯡ ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ ꯗꯣꯖꯁꯤꯡ ꯑꯁꯤ ꯍꯀꯊꯦꯡꯅꯅꯥ ꯏꯟꯇꯔꯆꯦꯟꯖ ꯇꯧꯕꯥ ꯌꯥꯗꯦ, ꯑꯃꯁꯨꯡ ꯚꯦꯂꯤꯗꯦꯠ ꯇꯧꯔꯕꯥ ꯏꯛꯌꯨꯏꯕꯦꯂꯟꯁ ꯑꯃꯠꯇꯥ ꯂꯩꯇꯦ꯫ ꯐꯣꯉꯕꯥ ꯀꯅꯕꯔꯁꯟ ꯇꯦꯕꯂꯁꯤꯡꯅꯥ ꯀꯟꯖꯔꯕꯦꯇꯤꯕ ꯑꯦꯞꯔꯣꯆ ꯑꯃꯥ ꯂꯧꯏ:
ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯁꯦꯛꯁꯟꯗꯥ ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 0.6–1.2 ꯄꯤꯕꯥ ꯄꯦꯁꯦꯟꯇꯁꯤꯡꯗꯥ: ꯃꯍꯧꯁꯥꯅꯥ ꯋꯦꯒꯣꯚꯤ ꯑꯁꯤ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 0.25ꯗꯒꯤ ꯍꯧꯏ꯫.
ꯅꯣꯡꯃꯗꯥ ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 1.8–2.4 ꯄꯤꯕꯥ ꯄꯦꯁꯦꯟꯇꯁꯤꯡꯗꯥ: ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 0.25 ꯅꯠꯠꯔꯒꯥ ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 0.5꯫.
ꯅꯣꯡꯃꯗꯥ ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 3ꯗꯥ ꯁ꯭ꯇꯦꯕꯜ ꯑꯣꯏꯕꯥ ꯄꯦꯁꯦꯟꯇꯁꯤꯡ: ꯁꯔꯚꯤꯁ ꯈꯔꯅꯥ (VA, CMIS) ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 0.5 ꯄꯤꯅꯕꯥ ꯄꯥꯎꯇꯥꯛ ꯄꯤꯔꯤ꯫ ꯑꯣꯐ-ꯂꯦꯕꯦꯜ ꯁ꯭ꯇꯥꯔꯇꯤꯡ ꯄꯣꯏꯟꯇ ꯑꯃꯥ ꯑꯣꯏꯅꯥ
ꯋꯦꯒꯣꯚꯤ ꯂꯦꯕꯦꯂꯅꯥ ꯔꯤꯀꯃꯦꯟꯗ ꯇꯧꯔꯀꯄꯒꯤ ꯃꯇꯨꯡ ꯏꯟꯅꯥ ꯃꯤꯒ꯭ꯔꯦꯗ ꯰.꯲꯵ꯗꯒꯤ ꯍꯧꯔꯒꯥ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯆꯦꯀꯁꯤꯅꯕꯥ ꯑꯃꯁꯨꯡ ꯂꯦꯕꯦꯂꯒꯥ ꯃꯥꯟꯅꯕꯥ ꯑꯣꯄꯁꯟ ꯑꯣꯏꯗꯨꯅꯥ ꯂꯩꯔꯤ꯫
ꯍꯧꯔꯀꯄꯒꯤ ꯗꯣꯖꯗꯒꯤ, ꯋꯦꯒꯣꯚꯤ ꯑꯁꯤ ꯅꯨꯃꯤꯠ 4 ꯈꯨꯗꯤꯡꯒꯤ ꯃꯤꯒ꯭ꯔꯦꯗ 1.7 ꯅꯠꯠꯔꯒꯥ ꯃꯤꯒ꯭ꯔꯦꯗ 2.4ꯒꯤ ꯃꯥꯌꯀꯩꯗꯥ ꯍꯦꯅꯒꯠꯍꯜꯂꯤ꯫ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯗꯣꯖ ꯑꯃꯥ ꯌꯥꯝꯅꯥ ꯐꯖꯅꯥ ꯇꯣꯂꯔ ꯇꯧꯔꯕꯗꯤ, ꯂꯦꯕꯦꯜ ꯑꯗꯨꯅꯥ ꯃꯊꯪꯒꯤ ꯑꯦꯁ꯭ꯀꯦꯂꯦꯁꯟ ꯑꯗꯨ ꯅꯨꯃꯤꯠ 4ꯅꯤ ꯊꯦꯡꯊꯍꯅꯕꯥ ꯌꯥꯏ꯫ ꯃꯤꯁ ꯗꯣꯖꯁꯤꯡꯗꯥ, ꯂꯦꯕꯦꯂꯗꯥ ꯍꯥꯌꯔꯤ ꯃꯗꯨꯗꯤ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯗꯣꯖ ꯑꯃꯥ ꯃꯥꯡꯈꯤꯕꯥ ꯑꯃꯁꯨꯡ ꯃꯊꯪꯒꯤ ꯗꯣꯖ ꯑꯗꯨ ꯅꯨꯃꯤꯠ ꯲ꯗꯒꯤ ꯍꯦꯟꯅꯥ ꯂꯩꯔꯕꯗꯤ ꯌꯥꯔꯤꯕꯃꯈꯩ ꯊꯨꯅꯥ ꯂꯧꯒꯗꯕꯅꯤ꯫ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯊꯪꯟ-ꯊꯪꯅꯅꯥ ꯗꯣꯖ ꯑꯅꯤ ꯅꯠꯠꯔꯒꯥ ꯃꯁꯤꯗꯒꯤ ꯍꯦꯅꯕꯥ ꯄꯤꯗꯕꯥ ꯇꯥꯔꯕꯗꯤ, ꯍꯦꯟꯅꯥ ꯅꯦꯝꯕꯥ ꯗꯣꯖ ꯑꯃꯗꯒꯤ ꯑꯃꯨꯛ ꯍꯟꯅꯥ ꯍꯦꯅꯒꯠꯂꯀꯄꯥ ꯃꯊꯧ ꯇꯥꯕꯥ ꯌꯥꯏ꯫
ꯅꯣꯡꯃꯩ ꯀꯥꯞꯄꯥ, ꯗꯥꯏꯔꯤꯌꯥ, ꯈꯣꯡ ꯍꯥꯝꯕꯥ ꯑꯃꯁꯨꯡ ꯈꯣꯡ ꯍꯥꯝꯕꯥ ꯑꯁꯤ ꯗ꯭ꯔꯒ ꯑꯅꯤꯃꯛꯀꯤ ꯈ꯭ꯕꯥꯏꯗꯒꯤ ꯀꯃꯟ ꯑꯣꯏꯕꯥ ꯑꯁꯣꯛ-ꯑꯄꯅꯁꯤꯡꯅꯤ꯫ STEP 8ꯗꯥ, ꯒꯦꯁ꯭ꯠꯔꯣꯏꯟꯇꯦꯁ꯭ꯇꯥꯏꯅꯦꯂꯒꯤ ꯊꯧꯗꯣꯀꯁꯤꯡ ꯑꯁꯤ ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ ꯁꯤꯖꯤꯟꯅꯔꯤꯕꯁꯤꯡꯒꯤ 84.1% ꯑꯃꯁꯨꯡ ꯂꯤꯔꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ ꯁꯤꯖꯤꯟꯅꯔꯤꯕꯁꯤꯡꯒꯤ 82.7%ꯅꯥ ꯔꯤꯄꯣꯔꯠ ꯇꯧꯈꯤ, ꯃꯈꯣꯌ ꯑꯌꯥꯝꯕꯅꯥ ꯃꯌꯥꯏ ꯑꯣꯏꯕꯥꯗꯒꯤ ꯃꯌꯥꯏ ꯑꯣꯏꯕꯥ ꯐꯥꯎꯕꯅꯤ꯫ ꯑꯗꯨꯝ ꯑꯣꯏꯅꯃꯛ, ꯂꯤꯔꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ (꯲꯷.꯶%)ꯗꯒꯤ ꯍꯦꯟꯅꯥ ꯁꯔꯨꯛ ꯌꯥꯔꯤꯕꯁꯤꯡꯅꯥ ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ (꯱꯳.꯵%) ꯂꯦꯄꯈꯤ꯫ ꯑꯄꯤꯀꯄꯥ ꯆꯥꯅꯕꯥ ꯆꯤꯟꯖꯥꯛ, ꯃꯄꯨꯡ ꯐꯥꯅꯥ ꯆꯥꯕꯥ ꯂꯦꯄꯍꯅꯕꯥ ꯑꯃꯁꯨꯡ ꯍꯥꯏꯗ꯭ꯔꯦꯠ ꯑꯣꯏꯅꯥ ꯂꯩꯕꯥ ꯑꯁꯤꯅꯥ ꯑꯌꯥꯝꯕꯥ ꯄꯦꯁꯦꯟꯇꯁꯤꯡꯗꯥ ꯑꯅꯧꯕꯥ ꯗꯣꯖꯒꯤ ꯈꯣꯡꯊꯥꯡ ꯈꯨꯗꯤꯡꯒꯤ ꯃꯇꯦꯡ ꯄꯥꯡꯏ꯫
ꯍꯧꯔꯀꯄꯒꯤ ꯋꯦꯒꯣꯚꯤ ꯗꯣꯖ ꯑꯁꯤ ꯅꯦꯝꯅꯥ ꯂꯩꯕꯅꯥ, ꯄꯦꯁꯦꯟꯇ ꯈꯔꯅꯥ ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 3ꯒꯤ ꯁꯦꯛꯁꯟꯗꯥ ꯊꯤꯡꯖꯤꯜꯂꯕꯥ ꯃꯇꯨꯡꯗꯥ ꯑꯍꯥꯅꯕꯥ ꯅꯨꯃꯤꯠ ꯈꯔꯅꯤꯗꯥ ꯆꯥꯛ ꯊꯣꯡꯕꯒꯤ ꯆꯥꯡ ꯈꯔꯥ ꯍꯜꯂꯀꯄꯥ ꯎꯏ꯫ ꯃꯁꯤ ꯃꯍꯧꯁꯥꯅꯥ ꯗꯣꯖ ꯍꯦꯅꯒꯠꯂꯀꯄꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯂꯦꯄꯈꯤ꯫ STEP 8ꯗꯥ, ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ ꯂꯧꯕꯥ ꯁꯔꯨꯛ ꯌꯥꯔꯤꯕꯁꯤꯡꯒꯤ 70.9%ꯅꯥ ꯌꯥꯃꯗ꯭ꯔꯕꯗꯥ 10%ꯒꯤ ꯑꯔꯨꯝꯕꯥ ꯍꯟꯊꯕꯥ ꯐꯪꯈꯤ, ꯃꯁꯤ ꯂꯤꯔꯥꯒ꯭ꯂꯨꯇꯥꯏꯗꯇꯥ 25.6%ꯒꯥ ꯆꯥꯡꯗꯝꯅꯕꯗꯥ ꯍꯦꯅꯒꯠꯈꯤ꯫ ꯔꯤꯖꯜꯇꯁꯤꯡ ꯑꯁꯤ ꯍꯧꯖꯤꯀꯁꯨ ꯗꯥꯏꯠ, ꯑꯦꯛꯇꯤꯚꯤꯇꯤ ꯑꯃꯁꯨꯡ ꯃꯤꯑꯣꯏ ꯑꯃꯒꯤ ꯕꯥꯏꯑꯣꯂꯣꯖꯤꯒꯤ ꯃꯈꯥ ꯄꯣꯜꯂꯤ꯫
ꯌꯥꯝꯅꯥ ꯊꯨꯅꯥ, ꯍꯦꯟꯅꯥ ꯂꯨꯝꯅꯥ ꯑꯔꯨꯝꯕꯥ ꯍꯟꯊꯍꯅꯕꯅꯥ 'ꯑꯣꯖꯦꯝꯄꯤꯛ ꯐꯦꯁ' ꯍꯥꯌꯅꯥ ꯀꯧꯕꯥ ꯇꯦꯝꯄꯜ, ꯆꯦꯛꯁꯤꯟ ꯑꯃꯁꯨꯡ ꯈꯣꯡꯗꯥ ꯚꯣꯜꯌꯨꯝ ꯍꯟꯊꯔꯀꯄꯥ ꯎꯕꯥ ꯐꯪꯏ꯫ ꯑꯦꯁ꯭ꯇꯦꯇꯤꯛ ꯀ꯭ꯂꯤꯅꯤꯀꯁꯤꯡꯅꯥ ꯑꯣꯖꯟ-ꯃꯦꯅꯦꯖꯃꯦꯟꯇ ꯄꯦꯁꯦꯟꯇꯁꯤꯡꯕꯨ ꯔꯤꯁ꯭ꯇꯣꯔꯇꯤꯕ ꯇ꯭ꯔꯤꯠꯃꯦꯟꯇꯁꯤꯡꯒꯥ ꯍꯦꯟꯅꯥ ꯄꯦꯌꯥꯔ ꯇꯧꯔꯤ꯫ ꯑꯩꯈꯣꯌꯒꯤ ꯑꯥꯔꯇꯤꯀꯜ꯫ ꯗꯥꯔꯃꯦꯜ ꯐꯤꯂꯔꯁꯤꯡꯅꯥ ꯑꯣꯖꯦꯝꯄꯤꯛ ꯐꯦꯁ ꯔꯤꯚꯔꯁ ꯇꯧꯕꯥ ꯉꯃꯒꯗ꯭ꯔꯥ? ꯃꯔꯃꯁꯤꯡ ꯑꯃꯁꯨꯡ ꯂꯥꯏꯌꯦꯡꯕꯒꯤ ꯑꯣꯄꯁꯅꯁꯤꯡꯅꯥ ꯑꯣꯄꯁꯅꯁꯤꯡ ꯑꯗꯨ ꯁꯟꯗꯣꯛꯅꯥ ꯇꯥꯛꯂꯤ꯫
ꯗ꯭ꯔꯒ ꯑꯅꯤ ꯑꯁꯤ ꯑꯣꯚꯔꯂꯦꯞ ꯇꯧꯕꯥ꯫ ꯑꯍꯥꯅꯕꯥ ꯋꯦꯒꯣꯚꯤ ꯏꯅꯖꯦꯀꯁꯟ ꯑꯗꯨꯒꯥ ꯅꯨꯃꯤꯠ ꯑꯗꯨꯃꯛꯇꯗꯥ ꯑꯔꯣꯏꯕꯥ ꯁꯦꯛꯁꯟꯗꯥ ꯗꯣꯖ ꯑꯃꯥ ꯂꯧꯔꯣꯏꯗꯕꯅꯤ꯫
2.4 mg ꯐꯥꯎꯕꯥ ꯍꯀꯊꯦꯡꯅꯅꯥ ꯂꯥꯞꯅꯥ ꯆꯠꯄꯥ꯫ ꯇꯤꯇꯥꯔꯦꯁꯟ ꯊꯥꯗꯣꯀꯄꯥ ꯑꯁꯤꯅꯥ ꯁꯥꯊꯤꯕꯥ ꯖꯤ.ꯑꯥꯏ.ꯒꯤ ꯔꯤꯑꯦꯛꯁꯅꯁꯤꯡ ꯑꯃꯁꯨꯡ ꯗꯤꯍꯥꯌꯗ꯭ꯔꯦꯁꯅꯒꯥ ꯃꯔꯤ ꯂꯩꯅꯕꯥ ꯀꯤꯗꯅꯤꯒꯤ ꯑꯁꯣꯛ-ꯑꯄꯅꯒꯤ ꯔꯤꯁ꯭ꯛ ꯍꯦꯅꯒꯠꯍꯜꯂꯤ꯫
ꯗꯣꯖꯁꯤꯡ ꯑꯁꯤ ꯃꯥꯟꯅꯕꯥ ꯃꯑꯣꯡꯗꯥ ꯂꯥꯌꯦꯡꯕꯥ꯫ ꯂꯤꯔꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ ꯃꯤꯒ꯭ꯔꯦꯗ ꯳ ꯑꯁꯤ ꯑꯀꯛꯅꯕꯥ ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ ꯗꯣꯖ ꯑꯃꯍꯦꯛꯇꯒꯥ 'ꯑꯃꯁꯨꯡ' ꯑꯣꯏꯗꯦ꯫
ꯗꯥꯏꯑꯦꯕꯦꯇꯤꯖꯒꯤ ꯍꯤꯗꯥꯛ-ꯂꯥꯡꯊꯀꯁꯤꯡ ꯌꯦꯡꯁꯤꯅꯕꯥ꯫ ꯏꯅꯁꯨꯂꯤꯟ ꯅꯠꯠꯔꯒꯥ ꯁꯂꯐꯣꯅꯥꯏꯜꯌꯨꯔꯤꯌꯥ ꯁꯤꯖꯤꯟꯅꯔꯤꯕꯥ ꯄꯦꯁꯦꯟꯇꯁꯤꯡꯅꯥ ꯍꯥꯏꯄꯣꯒ꯭ꯂꯥꯏꯁꯦꯃꯤꯌꯥ ꯊꯤꯡꯅꯕꯒꯤꯗꯃꯛ ꯗꯣꯖ ꯑꯦꯗꯖꯁ꯭ꯇꯃꯦꯟꯇ ꯇꯧꯕꯥ ꯃꯊꯧ ꯇꯥꯕꯥ ꯌꯥꯏ꯫
ꯑꯅꯔꯦꯒꯨꯂꯦꯇꯦꯗ 'ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ' ꯄꯣꯠꯊꯣꯀꯁꯤꯡ ꯁꯤꯖꯤꯟꯅꯗꯨꯅꯥ꯫ ꯄꯦꯁꯦꯟꯇꯁꯤꯡꯅꯥ ꯂꯦꯖꯤꯁ꯭ꯂꯦꯇꯤꯚ ꯐꯥꯔꯃꯥꯁꯤꯁꯤꯡꯗꯒꯤ ꯑꯣꯊꯣꯔꯥꯏꯖ ꯇꯧꯔꯕꯥ, ꯄ꯭ꯔꯦꯁ꯭ꯛꯔꯥꯏꯕ ꯇꯧꯔꯕꯥ ꯄꯣꯠꯊꯣꯀꯁꯤꯡ ꯈꯛꯇꯃꯛ ꯁꯤꯖꯤꯟꯅꯒꯗꯕꯅꯤ꯫
ꯑꯦꯁ꯭ꯇꯦꯇꯤꯛ ꯑꯃꯁꯨꯡ ꯋꯦꯂꯅꯦꯁ ꯀ꯭ꯂꯤꯅꯤꯀꯁꯤꯡꯒꯤ ꯑꯣꯏꯅꯗꯤ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯖꯤ.ꯑꯦꯜ.ꯄꯤ.-꯱ ꯊꯦꯔꯥꯄꯤ ꯍꯦꯅꯒꯠꯂꯀꯄꯅꯥ ꯑꯅꯥꯕꯁꯤꯡꯒꯤ ꯈꯣꯉꯆꯠꯁꯤꯡ ꯑꯃꯨꯛ ꯍꯟꯅꯥ ꯁꯦꯃꯒꯠꯂꯤ꯫ ꯃꯦꯗꯤꯀꯦꯜ ꯋꯦꯠ ꯃꯦꯅꯦꯖꯃꯦꯟꯇꯗꯥ ꯂꯩꯔꯤꯕꯥ ꯄꯦꯁꯦꯟꯇꯁꯤꯡꯅꯥ ꯑꯌꯥꯝꯕꯅꯥ ꯃꯈꯣꯌꯒꯤ ꯄ꯭ꯔꯣꯒ꯭ꯔꯥꯝ ꯑꯗꯨꯒꯤ ꯃꯅꯨꯡꯗꯥ ꯅꯠꯠꯔꯒꯥ ꯃꯇꯨꯡꯗꯥ ꯍꯀꯆꯥꯡ-ꯀꯟꯇꯨꯔꯤꯡ, ꯁ꯭ꯀꯤꯟ-ꯀ꯭ꯕꯥꯂꯤꯇꯤ ꯑꯃꯁꯨꯡ ꯚꯣꯜꯌꯨꯝ-ꯔꯤꯁ꯭ꯇꯣꯔ ꯇꯧꯕꯥ ꯂꯥꯏꯌꯦꯡꯁꯤꯡ ꯂꯧꯏ꯫ ꯑꯩꯈꯣꯌꯒꯤ ꯑꯣꯚꯔꯚꯤꯌꯨꯒꯤ ꯃꯇꯥꯡꯗꯥ... ꯲꯰꯲꯶ꯀꯤ ꯑꯣꯏꯅꯥ ꯃꯀꯣꯛ ꯊꯣꯡꯕꯥ ꯅꯟ-ꯁꯔꯖꯤꯀꯦꯜ ꯕꯣꯗꯤ ꯀꯟꯇꯨꯔꯤꯡ ꯑꯃꯁꯨꯡ ꯑꯣꯖꯟ ꯃꯦꯅꯦꯖꯃꯦꯟꯇ ꯇ꯭ꯔꯦꯟꯗꯁꯤꯡ ꯑꯁꯤꯅꯥ ꯗꯤꯃꯥꯟꯗ ꯑꯁꯤ ꯆꯠꯊꯔꯤꯕꯥ ꯃꯐꯃꯁꯤꯡꯒꯤ ꯃꯦꯄꯁꯤꯡ꯫
ꯑꯣꯖꯟ-ꯃꯦꯅꯦꯖꯃꯦꯟꯇ ꯄꯣꯔꯇꯐꯣꯂꯤꯑꯣ ꯑꯃꯥ ꯁꯦꯃꯒꯠꯂꯤꯕꯥ ꯕ꯭ꯔꯥꯟꯗꯁꯤꯡ ꯑꯃꯁꯨꯡ ꯗꯤꯁ꯭ꯠꯔꯤꯕ꯭ꯌꯨꯇꯔꯁꯤꯡꯅꯥ ꯃꯦꯗꯤꯀꯦꯜ ꯁꯨꯄꯔꯚꯤꯖꯅꯒꯤ ꯃꯈꯥꯗꯥ ꯂꯩꯕꯥ ꯄ꯭ꯔꯦꯁꯛꯔꯤꯄꯁꯟ ꯈꯛꯇꯒꯤ ꯑꯣꯏꯕꯥ ꯖꯤ.ꯑꯦꯜ.ꯄꯤ.-꯱ ꯀꯦꯌꯔ ꯑꯁꯤ ꯐꯤꯂꯔꯁꯤꯡ, ꯀꯣꯂꯥꯖꯦꯟ ꯁ꯭ꯇꯤꯝꯌꯨꯂꯦꯇꯔꯁꯤꯡ, ꯃꯦꯁꯣꯊꯦꯔꯥꯄꯤ ꯑꯃꯁꯨꯡ ꯍꯀꯆꯥꯡ ꯀꯟꯇꯨꯔꯤꯡ ꯏꯅꯖꯦꯀꯇꯦꯕꯂꯒꯨꯝꯕꯥ ꯀꯝꯞꯂꯥꯏꯑꯦꯟꯇ ꯑꯦꯗꯖꯨꯟꯇ ꯄ꯭ꯔꯗꯛꯇꯁꯤꯡꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯄꯦꯌꯥꯔ ꯇꯧꯒꯗꯕꯅꯤ꯫ ꯄ꯭ꯔꯥꯏꯚꯦꯠ-ꯂꯦꯕꯦꯜ ꯄꯥꯔꯇꯅꯔꯁꯤꯄꯁꯤꯡꯅꯥ ꯀꯔꯝꯅꯥ ꯊꯕꯛ ꯇꯧꯕꯒꯦ ꯍꯥꯌꯕꯗꯨ ꯈꯪꯅꯕꯒꯤꯗꯃꯛ, ꯄꯥꯕꯤꯌꯨ꯫ ꯑꯣ.ꯏ.ꯑꯦꯝ.ꯒꯤ ꯑꯔꯨꯝꯕꯥ ꯍꯟꯊꯍꯅꯕꯒꯤ ꯏꯅꯖꯦꯀꯁꯅꯁꯤꯡ ꯊꯤꯖꯤꯅꯕꯥ: ꯍꯀꯁꯦꯜ ꯑꯃꯁꯨꯡ ꯋꯦꯂꯅꯦꯁ ꯕꯤꯖꯤꯅꯦꯁꯁꯤꯡꯒꯤꯗꯃꯛꯇꯥ ꯁ꯭ꯠꯔꯦꯇꯦꯖꯤꯛ ꯑꯣꯏꯕꯥ ꯈꯨꯗꯣꯡꯆꯥꯕꯥ ꯑꯃꯥ . ꯑꯦ.ꯑꯣ.ꯑꯦꯝ.ꯑꯦ.ꯅꯥ ꯖꯤ.ꯑꯦꯝ.ꯄꯤ.ꯗꯥ ꯌꯨꯝꯐꯝ ꯑꯣꯏꯕꯥ ꯃꯦꯟꯌꯨꯐꯦꯀꯆꯔꯤꯡ, ꯔꯦꯒꯨꯂꯦꯇꯔꯤ ꯗꯣꯀꯨꯃꯦꯟꯇ ꯑꯃꯁꯨꯡ ꯀꯁ꯭ꯇꯝ ꯕ꯭ꯔꯥꯟꯗꯤꯡꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯄꯥꯔꯇꯅꯔꯁꯤꯡꯕꯨ ꯃꯇꯦꯡ ꯄꯥꯡꯏ꯫
ꯑꯌꯥꯝꯕꯥ ꯀꯦꯁꯁꯤꯡꯗꯥ, ꯍꯣꯌ꯫ ꯐꯣꯉꯕꯥ ꯒꯥꯏꯗꯂꯥꯏꯅꯁꯤꯡꯅꯥ ꯍꯥꯌꯔꯤ ꯃꯗꯨꯗꯤ ꯋꯥꯁꯛ ꯑꯃꯠꯇꯥ ꯃꯊꯧ ꯇꯥꯗꯦ, ꯑꯃꯁꯨꯡ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯑꯦꯖꯦꯟꯇ ꯑꯁꯤ ꯑꯔꯣꯏꯕꯥ ꯅꯣꯡꯃꯒꯤ ꯗꯣꯖꯒꯤ ꯃꯇꯨꯡ ꯅꯨꯃꯤꯠꯇꯒꯤ ꯍꯧꯕꯥ ꯌꯥꯏ꯫ ꯀꯔꯤꯒꯨꯝꯕꯥ ꯅꯍꯥꯛꯅꯥ ꯁꯥꯏꯗ ꯏꯐꯦꯛꯇꯅꯥ ꯃꯔꯝ ꯑꯣꯏꯗꯨꯅꯥ ꯍꯣꯡꯂꯛꯂꯤꯕꯥ ꯑꯣꯏꯔꯕꯗꯤ, ꯅꯍꯥꯛꯀꯤ ꯄ꯭ꯔꯦꯁ꯭ꯛꯔꯥꯏꯕꯔ ꯑꯗꯨꯅꯥ ꯅꯍꯥꯀꯄꯨ ꯂꯥꯏꯑꯣꯡꯁꯤꯡ ꯑꯗꯨ ꯂꯦꯄꯠꯔꯤꯐꯥꯎꯕꯥ ꯉꯥꯏꯅꯕꯥ ꯍꯥꯌꯔꯀꯄꯥ ꯌꯥꯏ꯫
ꯋꯦꯒꯣꯚꯤ ꯂꯦꯕꯦꯜ ꯑꯁꯤ ꯃꯤꯄꯨꯝ ꯈꯨꯗꯤꯡꯃꯛꯇꯥ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯃꯤꯒ꯭ꯔꯦꯗ ꯰.꯲꯵ꯗꯒꯤ ꯍꯧꯏ꯫ ꯀ꯭ꯂꯤꯅꯤꯀꯦꯜ ꯁꯔꯚꯤꯁ ꯈꯔꯅꯥ ꯁꯦꯛꯁꯟꯗꯥ 3 mgꯗꯥ ꯁ꯭ꯇꯦꯕꯜ ꯑꯣꯏꯕꯥ ꯑꯅꯥꯕꯁꯤꯡꯒꯤꯗꯃꯛꯇꯥ 0.5 mg ꯑꯁꯤ ꯑꯣꯐ-ꯂꯦꯕꯦꯜ ꯑꯣꯏꯅꯥ ꯂꯧꯏ꯫ ꯅꯍꯥꯛꯀꯤ ꯄ꯭ꯔꯦꯁ꯭ꯛꯔꯥꯏꯕꯔ ꯑꯗꯨꯅꯥ ꯅꯍꯥꯛꯀꯤ ꯇꯣꯂꯔꯦꯟꯁ ꯑꯗꯨꯗꯥ ꯌꯨꯝꯐꯝ ꯑꯣꯏꯗꯨꯅꯥ ꯋꯥꯔꯦꯞ ꯂꯧꯏ꯫
ꯅꯠꯇꯦ, ꯂꯦꯕꯦꯜ ꯑꯅꯤꯃꯛꯅꯥ ꯍꯥꯌꯔꯤ ꯃꯗꯨꯗꯤ ꯃꯈꯣꯌꯕꯨ ꯑꯇꯣꯞꯄꯥ ꯖꯤ.ꯑꯦꯜ.ꯄꯤ.-꯱ ꯔꯤꯁꯦꯄꯇꯔ ꯑꯦꯒꯣꯅꯤꯁ꯭ꯠ ꯑꯃꯒꯥ ꯄꯨꯅꯁꯤꯟꯅꯕꯅꯥ ꯔꯦꯀꯃꯦꯟꯗ ꯇꯧꯗꯦ꯫
ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 0.25ꯗꯒꯤ, ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 2.4 ꯐꯥꯎꯕꯗꯥ ꯅꯨꯃꯤꯠ 16ꯅꯤ ꯆꯪꯏ, ꯑꯃꯁꯨꯡ ꯅꯨꯃꯤꯠ 17ꯅꯤꯗꯒꯤ ꯃꯦꯟꯇꯤꯅꯦꯟꯁ ꯇꯧꯕꯒꯥ ꯂꯣꯌꯅꯅꯥ, ꯃꯤꯂꯤꯒ꯭ꯔꯥꯝ 0.5ꯗꯒꯤ ꯍꯧꯗꯨꯅꯥ ꯃꯁꯤ ꯆꯥꯎꯔꯥꯛꯅꯥ ꯅꯨꯃꯤꯠ 4ꯅꯤ ꯍꯟꯊꯍꯜꯂꯤ꯫
ꯑꯦꯁ.ꯇꯤ.ꯏ.ꯄꯤ.꯸ꯒꯤ ꯍꯦꯗ-ꯇꯨ-ꯍꯦꯗ ꯇ꯭ꯔꯥꯏꯑꯦꯂꯗꯥ, ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ ꯲.꯴ ꯃꯤꯒ꯭ꯔꯥꯅꯥ ꯆꯥꯡꯆꯠꯇꯥ ꯱꯵.꯸%ꯒꯤ ꯑꯔꯨꯝꯕꯥ ꯍꯟꯊꯍꯅꯈꯤꯕꯒꯥ ꯆꯥꯡꯗꯝꯅꯕꯗꯥ ꯅꯨꯃꯤꯠ ꯶꯸ꯗꯥ ꯂꯤꯔꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ ꯳.꯰ ꯃꯤꯒ꯭ꯔꯥꯒꯥ ꯂꯣꯌꯅꯅꯥ ꯶.꯴%ꯒꯤ ꯑꯔꯨꯝꯕꯥ ꯍꯟꯊꯍꯅꯈꯤ꯫ ꯃꯤꯑꯣꯏ ꯑꯃꯒꯤ ꯔꯤꯖꯜꯇꯁꯤꯡ ꯑꯁꯤ ꯇꯣꯉꯥꯟ-ꯇꯣꯉꯥꯅꯕꯥ ꯑꯣꯏ꯫
ꯑꯥꯔꯇꯤꯀꯜ ꯑꯁꯤ ꯖꯦꯅꯦꯔꯦꯜ ꯑꯦꯖꯨꯀꯦꯁꯅꯦꯜ ꯄꯥꯟꯗꯃꯁꯤꯡꯒꯤꯗꯃꯛ ꯑꯃꯁꯨꯡ ꯍꯦꯜꯊꯀꯦꯌꯔ ꯑꯃꯁꯨꯡ ꯏꯟꯗꯁ꯭ꯠꯔꯤꯒꯤ ꯄ꯭ꯔꯣꯐꯦꯁ꯭ꯅꯦꯂꯁꯤꯡꯒꯤꯗꯃꯛꯇꯅꯤ꯫ ꯃꯁꯤ ꯃꯦꯗꯤꯀꯦꯂꯒꯤ ꯄꯥꯎꯇꯥꯛ ꯅꯠꯇꯦ꯫ ꯁꯦꯛꯁꯟꯗꯥ ꯑꯃꯁꯨꯡ ꯋꯦꯒꯣꯚꯤ ꯑꯁꯤ ꯄ꯭ꯔꯦꯁꯛꯔꯤꯄꯁꯟ ꯈꯛꯇꯒꯤ ꯍꯤꯗꯥꯀꯁꯤꯡꯅꯤ꯫ ꯃꯇꯝ ꯑꯃꯁꯨꯡ ꯗꯣꯖ ꯌꯥꯎꯅꯥ ꯊꯦꯔꯥꯄꯤꯗꯥ ꯑꯍꯣꯡꯕꯥ ꯑꯃꯍꯦꯛꯇꯕꯨ, ꯃꯐꯃꯗꯨꯒꯤ ꯄ꯭ꯔꯦꯁ꯭ꯛꯔꯥꯏꯕ ꯇꯧꯔꯤꯕꯥ ꯏꯅꯐꯣꯔꯃꯦꯁꯅꯒꯤ ꯃꯇꯨꯡꯏꯟꯅꯥ ꯂꯥꯏꯁꯦꯟꯁ ꯄꯤꯔꯕꯥ ꯄ꯭ꯔꯦꯁ꯭ꯛꯔꯥꯏꯕꯔ ꯑꯃꯅꯥ ꯂꯦꯄꯊꯣꯛꯀꯗꯕꯅꯤ꯫ ꯑꯦ.ꯑꯣ.ꯑꯦꯝ.ꯑꯦ.ꯅꯥ ꯅꯣꯚꯣ ꯅꯣꯔꯗꯤꯁ꯭ꯛ ꯑꯦ/ꯑꯦꯁ.ꯀꯤ ꯇ꯭ꯔꯦꯗꯃꯥꯔꯛ ꯑꯣꯏꯔꯤꯕꯥ ꯁꯦꯛꯁꯟꯗꯥ ꯅꯠꯠꯔꯒꯥ ꯋꯦꯒꯣꯚꯤ ꯁꯥꯕꯥ ꯅꯠꯔꯒꯥ ꯌꯣꯅꯕꯥ ꯉꯃꯗꯦ꯫
ꯔꯨꯕꯤꯅꯣ ꯗꯤ.ꯑꯦꯝ., ꯒ꯭ꯔꯤꯅꯋꯦ ꯑꯦꯐ.ꯑꯦꯜ., ꯈꯥꯂꯤꯗ ꯌꯨ, ꯑꯃꯁꯨꯡ ꯑꯇꯩ꯫ ꯗꯥꯏꯑꯦꯕꯦꯇꯤꯖ ꯂꯩꯇꯕꯥ ꯑꯔꯨꯝꯕꯥ ꯍꯦꯅꯕꯥ ꯅꯠꯠꯔꯒꯥ ꯑꯣꯕꯦꯁꯤꯇꯤ ꯂꯩꯕꯥ ꯑꯍꯂꯁꯤꯡꯗꯥ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯁꯕꯛꯌꯨꯇꯦꯅꯤꯌꯝ ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ ꯕꯅꯥꯝ ꯅꯨꯃꯤꯠ ꯈꯨꯗꯤꯡꯒꯤ ꯂꯤꯔꯥꯒ꯭ꯂꯨꯇꯥꯏꯗꯅꯥ ꯍꯀꯆꯥꯡꯒꯤ ꯑꯔꯨꯝꯕꯥꯗꯥ ꯄꯤꯕꯥ ꯏꯐꯦꯛꯇ: STEP 8 ꯔꯦꯟꯗꯝ ꯑꯣꯏꯕꯥ ꯀ꯭ꯂꯤꯅꯤꯀꯦꯜ ꯇ꯭ꯔꯥꯏꯑꯦꯜ꯫ ꯖꯥꯃꯥ . ꯲꯰꯲꯲;꯳꯲꯷(꯲):꯱꯳꯸-꯱꯵꯰ꯗꯥ ꯐꯣꯉꯈ꯭ꯔꯦ꯫ ꯄꯤ.ꯑꯦꯝ.ꯑꯥꯏ.ꯗꯤ.: ꯳꯵꯰꯱꯵꯰꯳꯷ ꯂꯩ꯫
ꯑꯂꯃꯥꯟꯗꯣꯖ ꯖꯦ.ꯄꯤ., ꯂꯤꯡꯚꯥꯏ ꯑꯥꯏ, ꯃꯣꯔꯥꯂꯦꯁ ꯖꯦ, ꯑꯃꯁꯨꯡ ꯑꯇꯩ꯫ ꯒ꯭ꯂꯨꯀꯥꯒꯣꯅꯒꯨꯝꯕꯥ ꯄꯦꯄꯇꯤꯛ-꯱ ꯔꯤꯁꯦꯄꯇꯔ ꯑꯦꯒꯣꯅꯤꯁ꯭ꯇꯁꯤꯡꯒꯤ ꯃꯔꯛꯇꯥ ꯁꯣꯏꯆ ꯇꯧꯕꯥ: ꯔꯦꯁꯅꯑꯦꯜ ꯑꯃꯁꯨꯡ ꯄ꯭ꯔꯦꯛꯇꯤꯀꯦꯜ ꯒꯥꯏꯗꯂꯥꯏꯅꯁꯤꯡ꯫ ꯀ꯭ꯂꯤꯟ ꯗꯥꯏꯕꯦꯇꯤꯁ . ꯲꯰꯲꯰;꯳꯸(꯴):꯳꯹꯰-꯴꯰꯲ꯗꯥ ꯐꯣꯉꯈ꯭ꯔꯦ꯫ ꯄꯤ.ꯑꯦꯝ.ꯑꯥꯏ.ꯗꯤ.: ꯳꯳꯱꯳꯲꯵꯱꯰ꯗꯥ ꯊꯥꯕꯤꯔꯀꯎ꯫
ꯋꯦꯒꯣꯚꯤ (ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ) ꯏꯅꯖꯦꯀꯁꯟ/ꯇꯦꯕꯂꯁꯤꯡ, ꯌꯨ.ꯑꯦꯁ.ꯀꯤ ꯄ꯭ꯔꯦꯁꯛꯔꯤꯄꯁꯟ ꯏꯅꯐꯣꯔꯃꯦꯁꯟ, ꯅꯣꯚꯣ ꯅꯣꯔꯗꯤꯁ꯭ꯛ (ꯗꯦꯂꯤꯃꯦꯗ, ꯖꯨꯟ ꯲꯰꯲꯶ꯇꯥ ꯑꯄꯗꯦꯠ ꯇꯧꯈꯤꯕꯥ)꯫
SAXENDA (ꯂꯤꯔꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ) ꯏꯅꯖꯦꯀꯁꯟ, ꯌꯨ.ꯑꯦꯁ.ꯀꯤ ꯄ꯭ꯔꯦꯁꯛꯔꯤꯄꯁꯟ ꯏꯅꯐꯣꯔꯃꯦꯁꯟ, ꯅꯣꯚꯣ ꯅꯣꯔꯗꯤꯁ꯭ꯛ (DailyMed / FDA, 2026)꯫
ꯌꯨ.ꯑꯦꯁ.ꯀꯤ ꯚꯦꯇꯔꯥꯟ ꯑꯦꯐꯦꯌꯔꯁ ꯗꯤꯄꯥꯔꯇꯃꯦꯟꯇ꯫ ꯑꯔꯨꯝꯕꯥ ꯃꯦꯅꯦꯖꯃꯦꯟꯇꯀꯤꯗꯃꯛ ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ (WEGOVY) ꯁꯕꯛꯌꯨꯇꯦꯅꯤꯌꯝ ꯏꯅꯖꯦꯀꯁꯟ ꯀꯟꯕꯔꯁꯟ ꯒꯥꯏꯗꯂꯥꯏꯅꯁꯤꯡ, ꯐꯦꯕ꯭ꯔꯨꯋꯥꯔꯤ ꯲꯰꯲꯳꯫
ꯀ꯭ꯔꯥꯏꯁ꯭ꯇꯆꯔ ꯃꯦꯗꯤꯁꯤꯅꯁ ꯏꯅꯐꯣꯔꯃꯦꯁꯟ ꯁꯔꯚꯤꯁ꯫ ꯂꯤꯔꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ (ꯁꯛꯁꯦꯟꯗꯥ)ꯗꯒꯤ ꯁꯦꯃꯥꯒ꯭ꯂꯨꯇꯥꯏꯗ (ꯋꯦꯒꯣꯚꯤ)ꯗꯥ ꯍꯣꯡꯗꯣꯀꯄꯥ, ꯖꯨꯂꯥꯏ ꯲꯰꯲꯵꯫
ꯑꯦ.ꯑꯣ.ꯑꯦꯝ.ꯑꯦ.ꯒꯥ ꯎꯅꯕꯤꯌꯨ꯫
ꯂꯦꯕꯣꯔꯦꯇꯔꯤꯗꯥ ꯂꯩꯕꯥ ꯌꯨ.ꯑꯦꯁ
ꯄ꯭ꯔꯗꯛꯇ ꯀꯦꯇꯦꯒꯣꯔꯤꯒꯤ ꯃꯇꯥꯡꯗꯥ꯫
ꯕ꯭ꯂꯣꯒꯁꯤꯡ꯫